- BioHarvest Sciences (BHSC) has appointed Dr Rhona Applebaum as the company’s Senior Consultant for Regulatory and Environmental Affairs
- Dr Applebaum is an experienced leader in the food and regulatory sector, who previously worked for the Coca-Cola Company
- She will develop strategies for quick, cost-effective regulatory approval of company products, and conduct a sustainability assessment of its Biofarming technology
- Dr Applebaum will also help the company to apply its VINIA product to the pharma and medical food markets
- BioHarvest Sciences is up 8 per cent and is currently trading for C$0.14 per share
BioHarvest Sciences (BHSC) has appointed Dr Rhona Applebaum as the company’s Senior Consultant for Regulatory and Environmental Affairs.
Dr Applebaum is a widely recognised leader in the food and regulatory sector, with 40 years of experience under her belt. Prior to joining BioHarvest, she was the first Chief Science and Health Officer at the Coca-Cola Company, where she developed and executed the company’s global health and wellbeing strategy.
In her new position, Dr Applebaum will help BioHarvest to develop strategies for quick, cost-effective regulatory approval of the company’s products. This will include its Red Grape Cell product, VINIA, and other pipeline products currently in development.
Dr Applebaum will also assist the company in conducting a sustainability assessment of BioHarvest’s Biofarming technology, in comparison to conventional farming technologies.
Additionally, she will help the company to devise and execute a strategy for applying the VINIA product to the pharma and medical food markets.
BioHarvest’s CEO, Ilan Sobel, said the company could not be happier to have Dr Applebaum on the team, as it works to make its products available to multiple markets.
“We are privileged to have a leader in regulatory science and policy of Rhona’s calibre joining us at BioHarvest. We will benefit from her expertise in the food and health sectors,” he said.
“Her deep understanding of the complex relationships between industry, science, regulatory policy, and the public good is going to assist the company in bringing the wealth of the Biofarming technology to consumers across the globe,” he added.
Ilan went on to say that Rhona’s contribution will prove critical to the company’s goal of expanding its unique offerings to the pharma industry.
BioHarvest Sciences is up 8.00 per cent and is trading for C$0.14 per share, as of 2:52pm EST.